Research & Development
Appili Therapeutics Names Balboni as CEO
3 December 2019 - - Canadian clinical stage biopharmaceutical company Appili Therapeutics Inc. (TSX Venture: APLI) has appointed Dr. Armand Balboni to serve as its new chief executive officer, the company said.

As part of a planned transition, Balboni will replace former chief executive officer Kevin Sullivan, who has resigned to pursue other opportunities.

Balboni has served as Appili's chief scientific officer and a member of the company's board since 2018 and brings over 20 years of clinical and regulatory experience to the role of Appili CEO.

Balboni's healthcare experience includes medical and drug development acumen in both civilian and military organisations.

He is a founding partner and served as the senior advisor on scientific, regulatory, and medical affairs for the investment advisory firm Bloom Burton and Co., advising some of the most recent promising Canadian biotech companies.

Balboni is also a Commissioned officer in the US Army with 17 years of military service including as the Deputy director, Office of Regulated Activities, US Army Medical Materiel Development Activity (USAMMDA).

Balboni's work in the ORA focused on regulatory filings (Emergency Use Authorizations, meetings, pre-sub filings etc.) for military-relevant medical products across all therapeutic areas.

In addition, he completed a US Department of Defense fellowship at the US Food and Drug Administration's Center for Drug Evaluation and Research in the Division of Anti-infective Products, and in the Office of Counterterrorism and Emerging Threats. 

He also served as the Chief, Office of Research and Technology Application, at the US Army Research Institute of Infectious Disease (USAMRIID). 

Under his leadership, this office was responsible for the oversight of all strategic partnerships between USAMRIID and universities, US and foreign government agencies, and biotechnology and pharmaceutical companies.

Balboni has held various academic teaching positions including at Westfield State University, the University of Maryland University College, and the United States Military Academy at West Point.

He completed his doctoral work in the MD/PhD programme at the Icahn School of Medicine at Mount Sinai and his law degree at Brooklyn Law School.

Appili Therapeutics was founded to advance the global fight against infectious disease by matching clearly defined patient needs with drug development programs that provide solutions to existing challenges patients, doctors, and society face in this challenging disease space.

Appili has built a pipeline of assets designed to address a broad range of significant unmet medical needs in the infectious disease landscape.

This pipeline aims to address some of the most urgent threats in global public health. Appili acquired ATI-2307, a novel, broad spectrum, clinical stage antifungal, in development to address severe and difficult-to-treat invasive fungal infections.

Via an in-licensing programme, Appili acquired the rights to ATI-1701, a vaccine for tularemia, being developed to mitigate the risks of a very serious biological weapons threat.

ATI-1503 is a drug discovery program aimed at generating negamycin analogue candidates, which are a novel class of antibiotics with broad-spectrum activity against Gram-negative superbugs.

ATI-1501 employs Appili's proprietary, taste-masked, oral-suspension technology with metronidazole for the growing number of patients with difficulty swallowing.

Headquartered in Halifax, Nova Scotia, with offices in Mississauga, Ontario, Appili is pursuing worldwide opportunities in collaboration with science and industry commercial partners, governments and government agencies.


Related Headlines